Thanks for Nodus-ing: Basilea hands off pre­clin­i­cal on­col­o­gy pro­gram for $248M in on­go­ing an­ti-in­fec­tives piv­ot

Looks like Basilea Phar­ma­ceu­ti­ca is get­ting clos­er to its fi­nal days as an on­col­o­gy com­pa­ny.

The Switzer­land-based Roche off­shoot said Thurs­day that it had sold the com­pa­ny’s pre­clin­i­cal PARG check­point in­hibitor pro­gram to UK-based Nodus On­col­o­gy. PARG, or poly(ADP-ri­bose) gly­co­hy­dro­lase, is an en­zyme used to re­pair DNA dam­age and had been in­ves­ti­gat­ed as a po­ten­tial on­col­o­gy tar­get. Nodus will be part­ner­ing with Ger­man re­search in­sti­tute Lead Dis­cov­ery Cen­ter GmbH to con­tin­ue de­vel­op­ment of the pro­gram.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER